This article is more than 5 years old. Information may no longer be current.

Applied Genetic Technologies partners with Bionic Sight

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Applied Genetic Technologies Corp. announced that it has entered into a strategic research and development collaboration with Bionic Sight.

The companies seek to develop a new optogenetic therapy that leverages AGTC’s experience in gene therapy and ophthalmology and Bionic Sight’s neuro-prosthetic device and algorithm for retinal coding.

AGTC and Bionic Sight will seek to restore normal neural signaling in patients with visual deficits or blindness due to retinal disease.

“Bionic Sight has demonstrated an ability to mimic normal image formation in preclinical studies and we believe there is a potential to achieve an outcome for patients that greatly exceeds what is currently possible with prosthetic or gene therapy approaches in late-stage degenerative retinal diseases,” Sue Washer, president and CEO of AGTC said in a company press release.